GlassScriptPhysician profile
Taryn M Grattic
NPI 1093073926
$1,645.08
in general payments reported to CMS, 2019-2025
27 companies · $626 in 2025
The $626 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $293 · 2023: $108 · 2024: $96.83 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $199.82 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $157.54 | 2021-2025 | |
| Exact Sciences Corporation | $134.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $123.98 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $111.68 | 2021-2025 | Mounjaro |
| Amgen INC. | $106.39 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.10 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.91 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.77 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $37.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.09 | 2025 | Strensiq |
| Abbott Laboratories | $24.70 | 2021 | |
| Edwards Lifesciences Corporation | $24.44 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.85 | 2022 | |
| Boston Scientific Corporation | $23.56 | 2025 | Watchman Flx |
| Eisai INC. | $22.01 | 2022 | |
| Insulet Corporation | $19.89 | 2024 | Omnipod |
| Organon LLC | $19.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2021 | |
| Corcept Therapeutics | $17.10 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $16.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.46 | 2025 | |
| Hologic Sales and Service, LLC | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Grattic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.